IP Library Granted Patent US 8,772,291
Granted Patent B2
US 8,772,291 · App. 12/633,453 · Granted Jul 8, 2014

Multicyclic compounds and methods of their use

Inventors: Joseph Barbosa (Lambertville, NJ); Li Dong (Lawrenceville, NJ); Cynthia Anne Fink (Lebanon, NJ); Jiancheng Wang (Plainsboro, NJ); G. Gregory Zipp (Robbinsville, NJ)
Assignee: Lexicon Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,772,291
App. No.
12/633,453
Granted
Jul 8, 2014
Kind
B2
Abstract

This invention relates to multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use in, for example, the treatment of cognitive disorders.

Claims (26)

1. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein:

each of E 1 , E 2 and E 3 is independently N or CR 2 ;

each of G 1 and G 2 is independently N or CR 3 ;

each of R 1 , R 2 and R 3 is independently hydrogen, halogen, cyano, R A , OR A , C(O)R A , C(O)OR A , C(O)N(R A R B ), N(R A R B ), or SO 2 R A ;

each R 5 is independently halogen, cyano, R A , OR A , C(O)R A , C(O)OR A , C(O)N(R A R B ), N(R A R B ), or SO 2 R A ;

each R A is independently hydrogen or optionally substituted alkyl, aryl, arylalkyl, alkylaryl, heterocycle, heterocycle-alkyl, or alkyl-heterocycle;

each R B is independently hydrogen or optionally substituted alkyl, aryl, arylalkyl, alkylaryl, heterocycle, heterocycle-alkyl, or alkyl-heterocycle; and

n is 0-5.

2. The compound of claim 1 , wherein G 1 is N.

3. The compound of claim 1 , wherein G 2 is N.

4. The compound of claim 1 , wherein G 1 and G 2 are both N.

5. The compound of claim 1 , wherein each R 1 is hydrogen.

6. The compound of claim 1 , wherein E 1 is CR 2 .

7. The compound of claim 1 , wherein E 2 is CR 2 .

8. The compound of claim 1 , wherein E 3 is CR 2 .

9. The compound of claim 1 , wherein E 1 , E 2 and E 3 are all CR 2 .

10. The compound of claim 9 , wherein E 1 , E 2 and E 3 are all CH.

11. The compound of claim 10 , wherein at least one R 2 is halo.

12. The compound of claim 11 , wherein one of R 2 is chloro.

13. The compound of claim 1 , wherein n is 0.

14. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone.

15. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

16. A capsule or tablet comprising the pharmaceutical composition of claim 15 .

17. A pharmaceutical composition comprising a compound of claim 14 and a pharmaceutically acceptable excipient.

18. A capsule or tablet comprising the pharmaceutical composition of claim 17 .

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 5, 2026
From: OXFORD FINANCE LLC
To: LEXICON PHARMACEUTICALS, INC.; LEXICON PHARMACEUTICALS
Reel/Frame 075545/0601 →
SECURITY INTEREST Recorded May 4, 2026
From: LEXICON PHARMACEUTICALS, INC.; LEXICON PHARMACEUTICALS (NEW JERSEY), INC.; LION ACQUISITION CORPORATION
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 075498/0899 →
SECURITY INTEREST Recorded Mar 17, 2022
From: LEXICON PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 059432/0709 →
RELEASE OF SECURITY INTEREST Recorded Sep 14, 2020
From: BIOPHARMA CREDIT PLC
To: LEXICON PHARMACEUTICALS, INC.
Reel/Frame 053767/0445 →
SECURITY INTEREST Recorded Dec 20, 2017
From: LEXICON PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 044958/0377 →
Continuity (3)
Continuation 11433057 · May 12, 2006
Provisional Application 60680501 · May 13, 2005
Related Publication 20100081691A1 · Apr 1, 2010